Keytruda® or pembrolizumab, MSD’s (Merck in USA/Canada) monotherapy for metastatic small cell lung cancer (SCLC) has been granted accelerated approval by FDA. Keytruda® is now indicated for metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy.

This is the latest in the list of approved indications for use in SCLC, which has historically been a disease that has poor prognosis and limited treatment options. With this immunotherapy breakthrough to target non-SCLC using Keytruda®, eligible patients can seek new stem cell therapy for their cancer treatment. (Source)

MSD has been a long standing supporter of our biologics and cell therapy conferences at IMAPAC.

Meet other major cell therapy players at our Cell Therapy World Asia conference as well!